Paul R. Carter

Paul R. Carter is a seasoned international biopharmaceutical leader with over 25 years of senior executive experience, specializing in commercialization, regional alliances, and mergers and acquisitions. Mr. Carter is currently a Board Director for four publicly listed biopharma companies, which include HutchMed PLC, Mallinckrodt Pharmaceuticals plc, Immatics NV, and VectivBio Inc. He is also a member of the board of directors of several private companies, including Evox Therapeutics Ltd. Previously, Mr. Carter was the Executive Vice President and Chief Commercial Officer of Gilead Sciences Inc., where he was responsible for the company's worldwide commercial strategy and execution, including generating $33 billion of revenue in 2015 and launching several of the best-selling prescription drugs of all time. Prior to that, Mr. Carter held senior leadership roles in GSK, including head of GSK China and head of Smith Kline Beecham Russia. Mr. Carter is a Fellow of the Chartered Institute of Management Accountants in the UK and holds a degree in Business Studies from the University of West London.